Stimulation of the brain CCK 2 receptor by the C-terminal octapeptide CCK 8 of cholecystokinin (CCK) negatively modulates opioid responses. This suggests the existence of physiologically relevant interactions between endogenous CCK and opioid peptides, opening new perspectives particularly in the treatment of pain or drug addiction. CCK 2 receptor-deficient mice were used to analyze the incidence of this gene invalidation on opioid system. Compared with wild-type mice, mutants exhibited the following: (1) a hypersensitivity to the locomotor activity induced by inhibitors of enkephalin catabolism or by morphine; (2) a spontaneous hyperalgesia to thermal nociceptive stimulus, which was reversed by previous administration of the NMDA antagonist MK-801 [(ϩ)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate], and a large reduction in analgesic effects of endogenous or exogenous opioids; and (3) a more severe withdrawal syndrome after chronic morphine treatment. As expected, stimulation of , ␦, and D 2 receptors on brain tissue of wild-type animals induced a dose-dependent decrease in adenylate cyclase activity, whereas a striking mirror effect was observed in mutants. All of these results suggest that the absence, in knock-out mice, of the negative feedback control on the opioid system, normally performed out by CCK 2 receptor stimulation, results in an upregulation of this system. These biochemical and pharmacological results demonstrate the critical role played by CCK 2 receptors in opioid-dependent responses.
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The opioid peptides, in particular enkephalins, ␤-endorphin, and dynorphin, are involved in pain perception, cognitive functions, affective behaviors, and locomotion (for review, see Vaccarino et al., 1999) . These endogenous effectors induce their biological effects by interacting with three major classes of targets, designated , ␦, and receptors, which are widely distributed centrally and peripherally (Mansour et al., 1995) . The physiological actions of opioid peptides are regulated by a number of neuromodulators among them, the sulfated C-terminal octapeptide (CCK 8 ) of cholecystokinin (CCK) plays a crucial role (for review, see Cesselin, 1995; Wiesenfeld-Hallin et al., 1999) . CCK 8 , the predominant form found in the CNS (Rehfeld et al., 1985) , interacts with two different receptors, CCK 1 , which is abundant in peripheral tissues, and CCK 2 , which is the major type present in brain (Wank, 1995; Noble et al., 1999) . Anatomical studies have shown that the distribution of CCK 8 and CCK receptors is the same as that of endogenous opioid peptides and their receptors in several brain regions (for review, see Stengaard-Pedersen and Larsson, 1981; Gall et al., 1987; Skinner et al., 1997; Zhang et al., 2000) .
The CCK receptors modulate the opioid system in physiological processes, such as the control of pain or modulation of mood, including emotional and/or motivational responses (Crawley and Corwin, 1994; Daugé and Roques, 1995) . CCK 2 receptor stimulation reduces the analgesic action of morphine or the endogenous opioid peptides (Noble et al., 1993) protected by the enkephalin-degrading enzyme S) , which was shown to significantly increase the extracellular levels of enkephalins in brain structures (Daugé et al., 1996) . Accordingly, CCK 2 antagonists facilitate opioid-induced analgesia (Wiesenfeld-Hallin et al., 1990; Valverde et al., 1994) and antidepressant-like effects (Smadja et al., 1995) and increase the potency of RB 101 to reduce the severity of naloxone-precipitated withdrawal syndromes in rats that are chronically treated with morphine (for review, see Noble et al., 1999) . Conversely, opioids stimulate CCK release via their action on ␦ receptors, which in-turn negatively modulate opiate neurotransmission by activating CCK 2 receptors (Noble et al., 1993) . Numerous actions of opioids are reversed by dopamine antagonists, in agreement with the presence of opioid and dopamine targets on the same neurons, for example in mesolimbic and striatopallidal pathways (Van der Kooy et al., 1986; Manzanedo et al., 1999; Svingos et al., 1999) .
Mice lacking CCK 2 receptors (Nagata et al., 1996) provide a unique tool to investigate the counteractions between CCK and opioid systems by using complementary pharmacological and biochemical approaches. Behavioral responses involving opioid receptor activation, such as locomotion, analgesia, and withdrawal syndrome, were modified in mutant mice without observed changes in the binding parameters of and ␦ opioid receptors. In addition, the amount of endogenous opioids in the whole brain of these animals was significantly increased, as suggested by the reduction in the in vivo binding of the opioid antagonist [ 3 H]diprenorphine in knock-out mice. Finally, the adenylyl cyclase activity coupled to opioid or dopamine receptors, which is decreased in wild-type animals after activation of these targets, was strongly enhanced in mutant mice. All of these results strongly suggest that long-term deletion of the CCK 2 receptor induces an upregulation of the opioidergic system.
MATERIALS AND METHODS Animals
To isolate the mouse CCK 2 receptor gene, a mouse 129sv genomic library was screened with a human CCK 2 receptor cDNA probe, and the clone was inserted in a vector as described previously (Nagata et al., 1996) . J1 embryonic stem cells were electroporated with the linearized targeting vector. C lones displaying evidence for homologous recombination on the disrupted CCK 2 receptor gene were microinjected into blastocytes of C57BL /6J females. Germ line transmission occurred from the breeding of chimeric animals with C57BL /6J mice. To homogenize the genetic background of the mice, the first generation heterozygous were bred for 10 generations, with selection for the mutant CCK 2 gene at each generation. Fifth generation heterozygous were bred together to generate the CCK 2 receptor-deficient mice and control mice. Mice were housed by gender and genotype. Male and female mice (3 months old) were used, and each animal was used only once. At least 1 week before the experiments, they were housed in temperature-(22 Ϯ 1°C) and humidity-(50% Ϯ 5%) controlled conditions, with access to food and water ad libitum. The animals were treated in accordance with the NIH Guidelines for the Care and Use of Laborator y Animals (1985) , and the experiments were controlled by the ethical committee of the faculty.
Chemicals
RB 101 was synthesized in the laboratory as described previously (Fournié-Z aluski et al., 1992) 
Behavioral experiments
Actimeter. Mice were individually placed in plastic cages (255 ϫ 205 cm) that were isolated from noise and under a light intensity of 5 lux. Horizontal movements of the animals were monitored by photocells. RB 101 was injected intraperitoneally (60 and 80 mg / kg in a volume of 0.1 ml /10 gm). Morphine was injected subcutaneously (2 and 6 mg / kg in a volume of 0.1 ml /10 gm). Mice were tested immediately after injection of the chemicals for 60 min.
In another experiment, mice received 0.3 mg / kg (subcutaneously) of the nonspecific opioid antagonist naloxone, 15 min before the test.
Hot-plate test. A glass cylinder was used to keep the mouse on the heated surface of the plate, which was maintained at 52 Ϯ 0.5°C by a thermoregulated water-circulating pump. The hot-plate test was performed 20 min after injection of saline, RB 101 (80 mg / kg, i.p.), or morphine (2.5, 6, 9, and 18 mg / kg, s.c., in a volume of 0.1 ml /10 gm). NMDA antagonist (M K-801, 0.1 mg / kg, s.c.) and opioid antagonist (naloxone, 0.1 mg / kg s.c.) were administered 30 and 20 min before the hot-plate test, respectively. The jumping responses were measured. The percentage of analgesia was calculated as follows: percentage of analgesia ϭ (test latency Ϫ control latency)/(cutoff time Ϫ control latency) ϫ 100. The cutoff time was 240 sec. In these conditions, no tissue damage to the paws occurred. Results are expressed as means Ϯ SEM. The number of animals in each group was between 10 and 12.
Morphine withdrawal syndrome. Wild-type and CCK 2 R(Ϫ/Ϫ) mice were rendered opioid dependent by repeated intraperitoneal injection of morphine twice daily at an interval of 10 hr during 6 d. On day 6, the second daily injection of morphine was omitted. The morphine dose was progressively increased as follows: day 1, 20 mg / kg; day 2, 40 mg / kg; day 3, 60 mg / kg; day 4, 80 mg / kg; and days 5 and 6, 100 mg / kg. Control mice were treated with saline under the same conditions. Withdrawal was precipitated by 1 mg / kg naloxone injected subcutaneously, 2 hr after the last morphine injection. Mice were placed in a circular clear plastic observation area (30 ϫ 45 cm), and somatic signs were evaluated immediately after naloxone injection for a period of 30 min. The number of jumps, paw tremors, piloerection, and chewing frequency were counted. The time of ptosis and the degree of diarrhea were also evaluated. Results are expressed as mean Ϯ SEM. The number of animals in each group was between 10 and 12.
Biochemical experiments
In vivo binding of [ 3 H] diprenorphine. The experiments were performed as described previously . Mice were killed 15 min after intravenous injection of [ 3 H]diprenorphine (15 pmol in 0.2 ml of saline), and the brains were quickly removed and placed on ice. Total brain (minus cerebellum) was homogenized for 10 sec in 10 ml of ice-cold Tris-HC l buffer, pH 7.4, with a Brinkman Polytron. Aliquots of 0.15 ml were immediately filtered through Whatman (Maidstone, UK) GF/ B glass filters and rinsed twice with ice-cold buffer. Four filters were placed in a scintillation vial containing 15 ml of Wallac (PerkinElmer Life Sciences, Emery ville, CA) scintillation cocktail, and the radioactivity was counted. Each measure correspond to the mean Ϯ SEM of one experiment made in triplicate. Total radioactivity injected in each mouse was determined by counting 0.6 ml of the brain homogenate.
Binding of and ␦ opioid ligands. Mice were killed by decapitation. Whole brain minus cerebellum was dissected and homogenized in 10 vol (milliliters per gram of wet weight tissue) of ice-cold 0.25 M sucrose using a homogenizer. After centrif ugation at 1100 ϫ g (10 min), the pellet was rehomogenized in 5 vol of 0.25 M sucrose and recentrif uged at 1100 ϫ g (10 min). The combined supernatants were adjusted to a final dilution of 45 vol in 50 mM Tris-HC l, pH 7.4, 1 mM EDTA. The mixture was then centrif uged at 35,000 ϫ g for 30 min at 4°C, and the supernatant was discarded. The pellet (mitochondrial and microsomal membranes) was homogenized in 5 vol of ice-cold 0.25 M sucrose. Binding was performed by incubating 100 g of total brain membrane proteins in 50 mM Tris-HC l, pH 7.4, 1 mM EDTA at 25°C for 1 hr with [ 3 H]DAMGO or [ 3 H] N TI at concentrations of 0.075-0.06 and 0.01-0.02 nM, respectively. Nonspecific binding was determined by use of 2 M naloxone. Three or more experiments were performed in triplicate using separate membrane preparations. Binding data were analyzed using the EBDA-LIGAN D program (Biosoft, Stapleford, UK).
Determination of adenyl yl c yclase activit y. This experiment was performed as described previously (Brown et al., 1971; Noble and Cox, 1995) . Mice were killed by decapitation, and their brains were rapidly removed. Tissues were homogenized into buffer (in mM: 20 Tris-HC l, pH 7.4, 2 EGTA, 1 MgC l 2 , and 250 sucrose) and centrif uged at 27,000 ϫ g for 15 min at 4°C. The pellet was resuspended in fresh buffer and centrif uged again for 15 min. The supernatant was discarded, and the pellet was homogenized in 30% (w/ v) ice-cold buffer (2 mM Tris-HC l, pH 7.4, and 2 mM EGTA) for the determination of adenylyl cyclase activity. Tissue homogenate (15-30 g of protein in 10 l) was added to assay tubes (final volume of 60 l) containing (in mM): 80 Tris-HC l, pH 7.4, 10 theophylline, 1 MgSO 4 , 0.8 EGTA, 30 NaC l, 0.25 ATP, 0.01 GTP, and either the drug being tested or water. Triplicate samples for each treatment were incubated at 30°C for 5 min. The tubes were placed in boiling water for 2 min. The amount of cAM P formed was determined by addition of [ 3 H]cAM P (final concentration of 4 nM) in citrate-phosphate buffer, pH 5.0, and a binding protein was prepared from bovine adrenal glands. Additional samples were prepared, without tissue, containing known amounts of cAM P; they served as standards for quantification. The binding reaction was allowed to reach equilibrium by incubation for 90 min at 4°C, and the assay was terminated by the addition of charcoal and centrif ugation (1000 ϫ g for 10 min, at 4°C) to separate the free tritiated cAM P from that which was bound to the binding protein.
Aliquots of the supernatant containing bound cAM P were placed into scintillation vials, and Wallac scintillation cocktail was added.
Statistical analysis
Unless specified, all of the experiments were analyzed using a two-way ANOVA. If two-way ANOVA found significant differences, one-way ANOVA was performed, followed by a Dunnett's test or a Duncan's test.
RESULTS

Motor activity measured in actimeter
An increase of the spontaneous motor activity measured in actimeter for 60 min was observed in CCK 2 receptor-deficient mice compared with wild-type animals ( p Ͻ 0.05) (Fig. 1) . Compared with CD 1 mice , only a slight increase (not significant) was induced by intraperitoneal administration of RB 101 (60 or 80 mg/kg) in wild-type 129sv/C57BL/6. In the case of CCK 2 receptor-deficient mice, intraperitoneal administration of RB 101 at 60 and 80 mg/kg resulted in an important hyperactivity ( p Ͻ 0.01) (Fig. 1 A) . The subcutaneous administration of 2 mg/kg morphine produced no effect, whereas 6 mg/kg morphine significantly increased the motor activity of both wild-type ( p Ͻ 0.05) and knock-out ( p Ͻ 0.01) mice. Moreover, the motor activation was found greater in mutant than in wild-type mice ( p Ͻ 0.01) (Fig. 1 B) .
The increase of spontaneous motor activity observed for 60 min in CCK 2 receptor-deficient mice compared with wild-type animals was suppressed by the subcutaneous administration of the nonselective opioid antagonist naloxone (0.3 mg/kg) ( p Ͻ 0.05) (Fig. 2) .
Antinociceptive responses in the hot-plate test
A decrease of the spontaneous jump latency was observed in the mutant mice compared with the wild-type mice ( p Ͻ 0.01) (Fig.  3A) . This hyperalgesia was reversed by the NMDA antagonist MK-801 (0.1 mg/kg, s.c.) but was not significantly modified by naloxone administration (0.1 mg/kg, s.c.) (Fig. 3C) .
The injection of 80 mg/kg RB 101 only increased the jump latency in the wild-type mice but had no effect in mutant animals ( p Ͻ 0.01) (Fig. 3A) . Higher doses of RB 101 could not be used because of the low solubility of this inhibitor. Morphine was able to induce analgesia in the hot-plate test in wild-type animals with an ED 50 of 3 mg/kg and a maximum effect at 6 mg/kg. The dose-response curve induced by morphine in mutant animals was shifted to the right, with an ED 50 of 9 mg/kg and a maximum effect at 18 mg/kg (Fig. 3B) .
Withdrawal syndrome
Several behavioral manifestations of naloxone-evoked withdrawal were evaluated during a 30 min period immediately after naloxone administration (1 mg/kg, s.c.) in wild-type and mutant mice that had been chronically treated with saline or morphine (from 20 to 100 mg/kg, i.p., for 5 d) (Fig. 4) .
As expected, morphine treatment induced a strong physical dependence in both strains of mice. Thus, naloxone administration precipitated the standard behavior signs of withdrawal (increase in jumps, paw tremors, piloerection, chewing, and ptosis) in morphine-treated animals but not in saline-injected control groups.
Moreover, there was a significantly greater incidence of jumps, paw tremors, and chewing in mutant than in wild-type mice, whereas the time of ptosis was longer in ϩ/ϩ than in knock-out animals.
Concerning the diarrhea, wild-type animals treated with saline did not show any sign of diarrhea, in contrast to mutant mice. The incidence of this withdrawal sign was significantly increased in ϩ/ϩ animals treated with morphine compared with the control group but not in mutant mice.
In vivo binding of [ 3 H]diprenorphine
In vivo [ 3 H]diprenorphine binding was used to evaluate the endogenous opioid levels in mice. We observed a 22% decrease in specific binding of the [ 3 H]diprenorphine in knock-out mice compared with wild-type mice (wild-type mice, 100 Ϯ 4.3%; mutant mice, 77.6 Ϯ 6.7%; p Ͻ 0.05; Student's t test) (data not shown). This suggests that there is an increased extracellular amount of endogenous opioids in mutant mice that competes with [ 3 H]diprenorphine for opioid receptors binding.
Binding of and ␦ agonists
Scatchard analysis using specific -(DAMGO) and ␦-(NTI) radioligands showed similar plots in both ϩ/ϩ and Ϫ/Ϫ mouse brains. The total amount (B max ) of receptors in ϩ/ϩ and Ϫ/Ϫ mouse brains was 0.080 Ϯ 0.006 and 0.060 Ϯ 0.005 pmol/mg protein, respectively. The total amount of ␦ receptors was 0.069 Ϯ 0.007 and 0.060 Ϯ 0.006 pmol/mg protein, respectively (data not shown). The K D values were almost identical in wild-type and mutant mice (DAMGO, K D of 1.8 Ϯ 0.3 and 1.1 Ϯ 0.2 nM in wild-type and mutant mice, respectively; naltrindole, K D of 0.05 Ϯ 0.01 and 0.04 Ϯ 0.02 nM in wild-type and mutant mice, respectively).
Adenylyl cyclase activity
The -selective agonist DAMGO and the ␦-selective agonist DPDPE decreased the adenylyl cyclase activity of wild-type animals in a dose-dependent manner ( p Ͻ 0.01 at 10 M for both treatments), as reported previously (for review, see Childers, 1991) . In contrast, both agonists induced an increase in the adenylyl cyclase activity in mutant mice, which was statistically significant for DAMGO ( p Ͻ 0.05 at 10 M) but not for DPDPE. A t test revealed significant differences between the responses obtained with 0.1 M, 1 M ( p Ͻ 0.05), and 10 M ( p Ͻ 0.01) DAMGO or DPDPE in wild-type animals compared with knockouts (Fig. 5) .
The functionality of the dopamine D 2 receptors, which are also coupled to the adenylyl cyclase via a G i -protein (Albert et al., 1990) , was also examined. The D 2 agonist quinelorane induced a dose-dependent decrease in the amount of cAMP in wild-type mice ( p Ͻ 0.05 at 10 nM and 1 M; p Ͻ 0.01 at 100 nM; and p Ͻ 0.001 at 10 M) and a dose-dependent increase in the amount of cAMP ( p Ͻ 0.05 at 1 M and p Ͻ 0.01 at 10 M) in the knock-out mice. A t test revealed significant differences between wild-type and mutant mice at 1 and 10 M for the D 2 agonist ( p Ͻ 0.05 and p Ͻ 0.01, respectively) (Fig. 6 ).
DISCUSSION
Numerous studies have shown that CCK 8 is one of the most powerful endogenous antagonists of opioid system. Accordingly, CCK 2 receptor antagonists have been used to potentiate analgesia and antidepressant-like effects induced by endogenous or exogenous opioid agonists (for review, see Noble et al., 1999) . It has been established that CCK 2 and opioid receptors are colocalized in spinal cord and various brain structures (Gall et al., 1987) , but very few studies have attempted to investigate mechanisms underlying the interactions between both systems. Deletion of the CCK 2 receptor in mice provides an interesting model to explore such a modulation. Thus, in the present study, we used this model to achieve a better understanding of the role play by CCK 2 receptors on opioid system at the supraspinal level.
Locomotor activity measured in an actimeter showed that mutant mice had an enhanced basal activity compared with wild-type animals. This effect was reversed by the opioid antagonist naloxone, suggesting that the endogenous opioid system plays a role in the hyperlocomotion observed. This result was not attributable to an upregulation of the or the ␦ opioid receptors in CCK 2 receptor knock-out mice, because the binding parameters (K D and B max values) of -and ␦-selective ligands were similar in the brain of both strains of mice. Nevertheless, the lack of changes in opioid receptors density measured in the whole brain minus cerebellum cannot exclude that decrease and/or Figure 5 . Effect of the selective opioid agonist DAMGO ( A) and the selective ␦ opioid agonist DPDPE ( B) on adenylyl cyclase activity in wild-type (f) and mutant (Ⅺ) mice. Results are expressed as the mean Ϯ SEM percentage of basal adenylyl cyclase activity from five or more independent experiments, each performed in triplicate.
ૺ p Ͻ 0.05, ૺૺ p Ͻ 0.01, ૺૺૺ p Ͻ 0.001 compared with the control wild-type mice (Student's t test).
૾૾ p Ͻ 0.01 compared with the mice treated with 1 nM either agonist (Dunnett's t test) . increase in B max values could take place with a regional selectivity. One of the possibilities accounting for the spontaneous hyperlocomotor activity observed could be an increase in the endogenous opioid agonist tone in the brain of mutant mice, because other studies have shown that selective opioid agonists increase locomotor activity in rodents (Kalivas et al., 1985; Calenco-Choukroun et al., 1991; Baamonde et al., 1992) . This was investigated by measuring the in vivo binding of [ 3 H]diprenorphine. Accordingly, the total amount of endogenous opioid ligands able to compete for [ 3 H]diprenorphine was found enhanced in the brain of mutant compared with wild-type mice. This result could be expected, because previous studies have indirectly suggested a tonic inhibitory action of CCK through CCK 2 receptor activation to diminish the release of endogenous opioid peptides (Suh et al., 1992; Noble et al., 1993; Nichols et al., 1996) . This hypothesis was in good agreement with the fact that CCK 2 antagonists strongly potentiate RB 101-induced antinociceptive responses and antidepressant-like effects (Valverde et al., 1994; Smadja et al., 1995) . Nevertheless, one cannot exclude that the higher hyperlocomotion induced by morphine or the dual inhibitor of enkephalin-degrading enzymes RB 101 in mutant mice compared with wild-type animals also involves other regulatory processes occurring within the dopaminergic system of mutant animals, because it is well established that hyperlocomotion induced by basal or tonic stimulation of opioid receptors is related to dopamine receptor activation . Hot-plate experiments were then performed to measure the nociceptive responses and the analgesia mediated by supraspinal mechanisms in CCK 2 receptor-deficient mice. Surprisingly, mutant mice exhibited a lower nociceptive threshold than wild-type animals. This could be a consequence of the slight increase in endogenous opioid peptides, suggested by the decrease in [
3 H]diprenorphine binding. Indeed, it has been shown that the mixed enkephalin-degrading enzyme inhibitor RB 101 used at low doses that slightly increase the level of endogenous opioid ligands, mimicking the situation observed in knock-out mice, elicits paradoxical hyperalgesia (Willer et al., 1990; Noble et al., 1994) . Another hypothesis could be an imbalance in antinociceptivepronociceptive systems. Indeed, it has been proposed that opiates concomitantly activate both pathways and, more specifically, the NMDA-dependent pronociceptive system (Larcher et al., 1998; Célèrier et al., 2001) . This is in good agreement with the results obtained in the present study, because the hyperalgesia observed was totally reversed by the NMDA-antagonist MK-801. Thus, the slight increase in endogenous opioid peptides may be involved in the enhancement of sensitivity of postsynaptic excitatory amino acid (NMDA) receptor and modulation of primary afferent neurotransmission, including nociception, leading to hyperalgesia (Cerne et al., 1992) . On the other hand, mutant mice were less sensitive to the analgesic effect of endogenous (RB 101) or exogenous (morphine) opioid agonists. Although the binding characteristics of opioid receptors were not statistically different between mutant and wild-type mice, a difference in the coupling to G-proteins could not be excluded. This was investigated by studying the ability of adenylyl cyclase to inhibit cAMP production, which is one of the most important second messengers in the opioid receptor transduction pathway (for review, see Cox, 1993) . Strikingly, the activation of and ␦ receptors in knock-out mice did not decrease the formation of cAMP, as observed in wildtype animals, but significantly increased cAMP production. This increase of cAMP formation may account for the lack of analgesic responses observed in mutant mice because previous studies have shown that upregulation of the cAMP pathway induces excitatory effects in dorsal root ganglion neurons leading to hyperalgesia (Cerne et al., 1992; Randic et al., 1995; Vanegas and Schaible, 2001) .
These results suggest that stimulation of CCK 2 receptors play an important role to keep the opioid receptors coupled to the G i -proteins with subsequent decrease in cAMP production. Several hypotheses may account for the observed increase in cAMP production induced by opioids in mutant mice. (1) Deletion of the CCK 2 receptor could impair the association of G i␣ to the opioid receptors, thus reducing the inhibition of adenylyl cyclase activity. In good agreement with this hypothesis, blockade of the ␣ i subunit by pertussis toxin triggers an increase in cAMP production after opioid receptor stimulation (Sarne et al., 1998) . (2) It has been shown that phospholipase C-specific inhibitors blocked opioid receptor-mediated inhibition of adenylyl cyclase activity (Fan et al., 1998) . Because CCK 2 receptor stimulation induces phospholipase C activation, it could be speculated that deletion of this receptor inhibits the negative coupling to adenylyl cyclase, thus revealing another signaling pathway with an increase in cAMP production.
In addition, the D 2 dopamine receptors, which interact with the CCK network and which are normally negatively coupled to adenylyl cyclase (Hökfelt et al., 1980; Albert et al., 1990; Crawley, 1991) , were also found to be positively coupled to the cAMP pathway in mutant mice. Thus, as for and ␦ opioid receptors, CCK 2 receptors appear to be critical in the negative coupling of D 2 receptors to the adenylyl cyclase pathway. This change in the transduction processes coupled to the D 2 receptors may also account for the hyperlocomotion observed in mutant animals described above.
At last, morphine was chronically administered to both strains of mice to investigate the role of CCK 2 receptors in physical signs of opioid withdrawal. It appeared that the major withdrawal signs were more severe in mutant mice than in wild-type animals. Because several studies have shown that chronic morphine treatments enhance cAMP levels in wild-type animals (Nestler and Aghajanian, 1997) , these results could be attributable to the cumulative increase in adenylyl cyclase activity observed in untreated mutant mice and the one triggered by the chronic morphine treatment.
In conclusion, our results show that CCK 2 receptors play a crucial role in the homeostasis of the opioid system at the supraspinal level. Until now, only acute or repetitive treatment over a very short period with CCK 2 receptor antagonists had been used in association with opioid agonists, leading to a potentiation of the analgesic effects of opioids (Wiesenfeld-Hallin et al., 1990; Valverde et al., 1994) and to a reduction of the severity of the withdrawal syndrome (for review, see Noble et al., 1999) . However, the absence, in knock-out mice, of the negative feedback control on the opioid system, normally performed by CCK 2 receptor stimulation, results in an upregulation of this system, with a positive coupling of the and ␦ opioid receptors to the adenylyl cyclase pathway. This may account for the hypersensitivity to the locomotor activity induced by morphine or RB 101, the hyposensitivity toward the antinociceptive effects of these compounds, and the more severe withdrawal syndromes observed in these genetically modified animals after chronic morphine treatment. Assays on spinal tissues in the CCK 2 receptor-deficient mice have to now be performed, because it is well established that CCK interacts with opioid system in the spinal cord.
